AboutNeuron TypesElectrophysiology PropertiesArticlesFAQsData/APIGet Involved

Article: Development of dendritic tonic GABAergic inhibition regulates excitability and plasticity in CA1 pyramidal neurons.

Full Text (publisher's website) ; Article Metadata ; Article Data (extracted)
Groen MR; Paulsen O; Pérez-Garci E; Nevian T; Wortel J; Dekker MP; Mansvelder HD; van Ooyen A; Meredith RM
J. Neurophysiol., 2014


Table 1.

Active and passive properties of young (postnatal days 14-19) and mature (postnatal days 28-46) CA1 pyramidal neurons based on spike profile before and after the application of the GABA(A) targeted drugs gabazine (10 μM and 200 nM), THIP, and L-655,708, or artificial cerebrospinal fluid

Vm, mVRm, MΩτ, msAP Threshold, mVAP Halfwidth, msAP Peak, mV
nPrePostPrePostPrePostPrePostPrePostPrePost
Young CA1 pyramidal neurons
Control8-64.1 ± 1.5-58.1 ± 1.1181.6 ± 12.4179.5 ± 23.531.0 ± 3.639.2 ± 6.8-41.8 ± 0.5-40.8 ± 0.41.32 ± 0.071.23 ± 0.0671.6 ± 2.973.1 ± 3.1
Gabazine (10 μM)17-65.9 ± 0.8-59.6 ± 1.1160.8 ± 11.6157.7 ± 14.130.8 ± 2.635.1 ± 4.2-43.9 ± 1.0-42.0 ± 1.41.44 ± 0.091.33 ± 0.0873.3 ± 1.972.3 ± 2.2
Pre-post**ns**ns*ns
Drug pre-post*nsnsnsnsnsns
Mature CA1 pyramidal neurons
Control7-65.6 ± 1.2-60.6 ± 1.5126.3 ± 15.3100.6 ± 10.027.5 ± 2.724.3 ± 2.1-43.6 ± 2.2-41.8 ± 1.61.32 ± 0.121.12 ± 0.0890.1 ± 3.285.5 ± 2.9
Gabazine (10 μM)14-64.6 ± 0.8-58.9 ± 1.5110.9 ± 8.891.6 ± 7.831.7 ± 4.227.4 ± 2.3-41.1 ± 1.0-38.3 ± 1.61.20 ± 0.061.08 ± 0.0478.5 ± 2.177.1 ± 1.6
Gabazine (200 nM)5-69.3 ± 1.4-60.9 ± 0.7103.8 ± 8.294.5 ± 7.420.6 ± 1.520.2 ± 2.9-47.6 ± 1.1-40.4 ± 2.31.14 ± 0.041.03 ± 0.0475.5 ± 1.877.1 ± 3.0
THIP7-65.3 ± 0.8-60.6 ± 1.5125.6 ± 16.088.2 ± 8.424.3 ± 2.717.3 ± 1.4-42.0 ± 1.5-39.7 ± 2.01.27 ± 0.051.28 ± 0.0889.4 ± 2.481.5 ± 4.6
L-655,7087-64.8 ± 1.6-60.5 ± 0.9148.4 ± 34.4106.1 ± 6.518.7 ± 1.113.6 ± 2.4-48.5 ± 0.8-44.7 ± 1.11.25 ± 0.061.13 ± 0.0481.3 ± 2.576.9 ± 3.6
Pre-post****ns******
Drug pre-post*nsnsnsnsnsns

  • Values are means ± SE; n, no. of neurons. Vm, membrane potential; Rm, input resistance; τ, time constant; AP, action potential; Pre, before application; Post, after application. Tonic inhibition does not alter somatic passive and active properties. Active and passive properties of preadolescent (postnatal days 14-19) and adolescent (postnatal days 28-46) CA1 pyramidal neurons based on spike profile before (pre) and after (post) the application of the GABA(A) targeted drugs [gabazine (10 μM and 200 nM), THIP, and L-655,708] or artificial cerebrospinal fluid are shown. Statistical analysis is based on repeated-measures mixed ANOVA. Significant difference:

  • ↵* P < 0.05,

  • ↵** P < 0.01, or not significant (ns).


Report miscurated data

Inferred neuron-electrophysiology data values

Neuron Type Neuron Description Ephys Prop Extracted Value Standardized Value Content Source
Hippocampus CA1 pyramidal cell spike threshold -40.8 ± 0.4 (8) -40.8 (mV) Data Table
Hippocampus CA1 pyramidal cell spike half-width 1.23 ± 0.06 (8) 1.23 (ms) Data Table
Hippocampus CA1 pyramidal cell spike amplitude 73.1 ± 3.1 (8) 73.1 (mV) Data Table
Hippocampus CA1 pyramidal cell resting membrane potential -58.1 ± 1.1 (8) -58.1 (mV) Data Table
Hippocampus CA1 pyramidal cell resting membrane potential -60.6 ± 1.5 (7) -60.6 (mV) Data Table
Hippocampus CA1 pyramidal cell input resistance 100.6 ± 10.0 (7) 100.6 (MΩ) Data Table
Hippocampus CA1 pyramidal cell membrane time constant 24.3 ± 2.1 (7) 24.3 (ms) Data Table
Hippocampus CA1 pyramidal cell spike threshold -41.8 ± 1.6 (7) -41.8 (mV) Data Table
Hippocampus CA1 pyramidal cell spike half-width 1.12 ± 0.08 (7) 1.12 (ms) Data Table
Hippocampus CA1 pyramidal cell spike amplitude 85.5 ± 2.9 (7) 85.5 (mV) Data Table
Hippocampus CA1 pyramidal cell input resistance 179.5 ± 23.5 (8) 179.5 (MΩ) Data Table
Hippocampus CA1 pyramidal cell membrane time constant 39.2 ± 6.8 (8) 39.2 (ms) Data Table